Oncopeptides (ONCO.ST) Stock Analysis & AI Equity Report
Oncopeptides (ONCO.ST) overview
Oncopeptides (ONCO.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Oncopeptides reported revenue of SEK 71.1m and operating profit of SEK -226m; the year-end share price was 4.81 SEK and market capitalisation was SEK 1,091m. Oncopeptides is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Oncopeptides's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Oncopeptides
Oncopeptides AB is a Swedish biotechnology company focused on developing, commercializing and expanding targeted therapies for difficult-to-treat cancers. Its main product is Pepaxti for multiple myeloma, which it is commercializing in Europe. The company also develops a pipeline of drug candidates through its proprietary PDC and SPiKE technology platforms.
Generate the Oncopeptides report
Oncopeptides is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Oncopeptides and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.